Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: TATRADER who wrote (52630)	1/6/2006 8:41:47 AM
From: hotlinktuna	Read Replies (1) \| Respond to of 59879

MIVT 1.03 may see some action with this PR: SmallCap Sentinel: Biotech Companies Chase Billion Dollar Markets Friday January 6, 6:30 am ET IRVINE, Calif., Jan. 6, 2006 (PRIMEZONE) -- ``Biotech companies, in anticipation of a greatly expanding market based upon a large segment of the population hitting their elder years, are positioning and executing their business plans with some degree of fervor,'' said SmallCap Sentinel analyst, D.R. Clark. ``Companies large and small want a piece of this perceived cash cow.'' ``MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News), for example, has been active in pursuing its initiatives in research and development while strengthening their business plan with financing and management additions,'' said Clark. ``Clearly, the company wants to be 'ready' for successful entry to this burgeoning market.'' ADVERTISEMENT MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on a broad range of other implantable medical devices. The company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the interaction with metal stents. The company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility, pursued by the science in the field of advanced implantable drug delivery systems. An informational report, ``The Silver Tsunami: Baby Boomers and Biotech Breakthroughs'' is available free of charge at smallcapsentinel.com The report addresses issues related to emergent biotechnology potentially affecting companies including Johnson and Johnson (NYSE:JNJ - News), Pfizer Inc. (NYSE:PFE - News), and Merck (NYSE:MRK - News). Interested parties may view additional information about MIVT via this direct link: trilogy-capital.com Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience. All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies. Contact: Market Pathways and StockUpTicks Shannon Squyres, Editor (949) 955-0107 -------------------------------------------------------------------------------- Source: SmallCap Sentinel; MIV Therapeutics, Inc.

To: TATRADER who wrote (52630)	1/7/2006 1:59:55 AM
From: GTC Trader	Read Replies (2) \| Respond to of 59879

<< STEM is on my Friday watch list...I would like it to edge tomorrow toward 3.40 in first 20 minutes, then we buy it and set a stop at 3.25, look for 20-30 cent bounce >> bigcharts.marketwatch.com Mark, You certainly picked the right day for this trade! Sorry it didn't make it from your watch list to your account. STEM was flat for 4.5 hours, and then ramped up the rest of the day closing at the high at 3.76. You could have gotten your 20-30 cents by buying around 3.50 and selling the close. Plan the trade and trade the plan. I like your plan, but mine was different. I see 3.40 as strong support and the downtrend from the September high as being important. Today, STEM busted through that downtrend line after putting in a double bottom earlier in the week. bigcharts.marketwatch.com It closed right on the 20d sma. For me, this is a longer term play with a target of possibly $5. Right now, the $4 area is key. I would like to see STEM take out $4 early next week on high volume. If it breaks through 4 but stalls around 4.50, then I will sell at that time. Your plan may be better than mine, but I am sticking to my plan. Better to be disciplined and stick to ones guns, such as they are! :o) Thanks, Coach! Still learning - Ken